Recent Postings to


Worst Pills, Best Pills Newsletter Articles

  View the entire February 2019 issue in PDF format

  View the entire January 2019 issue in PDF format

  • Important Clopidogrel (PLAVIX) Drug Interactions
    (January 2019)
    Read about the many prescription and over-the-counter medications that can interact in dangerous ways with clopidogrel, a widely used anti-platelet drug.
  • Florida Clinic Brazenly Deceives Patients About a Cancer “Treatment”
    (January 2019)
    In his editor’s column, Dr. Michael Carome recounts how a Florida medical clinic deceived patients by falsifying scientific journal citations in its promotion of a now-illegal heart-toxic drug called cesium chloride for treatment of cancer.
  • FDA Warns About Serious Genital Infections With Newest Class of Diabetes Drugs
    (January 2019)
    Learn about a rare but potentially fatal bacterial infection in the area of the genitals that has been linked to the diabetes drugs known as sodium-glucose cotransporter-2 inhibitors, commonly called “flozins.”
  • New Study Links Statins to a Rare Autoimmune Muscle Disorder
    (January 2019)
    In this article, we review new research showing that statins are associated with a potentially disabling autoimmune muscle disorder known as idiopathic inflammatory myositis, a rare disorder that is distinct from the much more common type of muscle injury seen with statins.
  • Review of the Parkinson’s Disease Drug Apomorphine (APOKYN)
    (January 2019)
    Find out about the risks and benefits of apomorphine, an injectable medicine approved by the FDA for treatment of specific symptoms that occur in patients with advanced Parkinson’s disease.
  • Question & Answer
    (January 2019)
    In response to a reader’s question about our article “Metformin: First-Choice Drug for Type 2 Diabetes” in the August 2018 issue, we discuss the risk of diarrhea and other adverse gastrointestinal effects that may occur when taking metformin.

  View the entire December 2018 issue in PDF format

Additional Information from Public Citizen

  • (February 1, 2019)
    In testimony before a joint meeting of the FDA’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee, Public Citizen urged the committees to recommend that the FDA immediately remove from the market the widely used gout medication febuxostat because it poses unique, serious risks – include the risk of dying from cardiovascular disease – but offers no unique benefit. Public Citizen had requested such action in a citizen petition submitted to the agency on June 21, 2018.
  • (February 1, 2019)
    In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Bone, Reproductive and Urologic Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject Amgen’s new drug application for romosozumab for treatment of osteoporosis in postmenopausal women at high risk for fracture because of clinical trial data linking the drug to an increased risk of serious adverse cardiovascular events.
  • (February 1, 2019)
    In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Endocrinologic and Metabolic Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject Sanofi’s new drug application for sotagliflozin for treatment of type 1 diabetes because the drug offers minimal benefits that do not outweigh the significantly increased risk of life-threatening diabetic ketoacidosis.
  • (January 1, 2019)
    In a letter to Dr. Scott Gottlieb, the Food and Drug Administration (FDA) Commissioner, Public Citizen and the chair of the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee explain how the Commissioner misled the public regarding potential “unique” benefits of Dsuvia, a controversial, highly potent opioid pain relief medication.
  • (December 3, 2018)
    The Food and Drug Administration (FDA) is recklessly and needlessly endangering people by approving a super-strong opioid, Public Citizen and the head of a key FDA advisory committee said today. The FDA gave the green light for the medication, which is called sufentanil sublingual tablet (brand name Dsuvia) and is to be used to treat moderate-to-severe acute pain in a medically supervised setting. It is five to 10 times more potent than fentanyl and 1,000 times more potent than morphine.